Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rota-V-Aid is a pentavalent, live-attenuated oral vaccine developed by Pharm Aid for the prevention of rotavirus infection in infants. It is a freeze-dried formulation that, upon reconstitution, is administered orally in a three-dose regimen. The vaccine targets five common rotavirus serotypes (G1, G2, G3, G4, and G9), providing broad-spectrum protection against rotavirus-induced gastroenteritis. It works by stimulating the body's immune system to produce antibodies against these specific rotavirus strains, thereby preventing severe diarrheal disease. The vaccine is often localized in Russia through partnerships with international manufacturers like the Serum Institute of India.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rota-V-Aid (Serum Institute of India).